Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | HINT1 | P49773 | 9/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408372 | 0.90 | TYMP (0.37) | TYMPHPGDTAAR1HINT1POLB | |
| SCHEMBL6316021 | 0.90 | TYMP (0.39) | TYMPHPGDTAAR1HINT1POLB | |
| SCHEMBL6231468 | 0.90 | TAAR1 (0.37) | TYMPHPGDTAAR1HINT1POLB | |
| SCHEMBL6735187 | 0.83 | TRDMT1 (0.34) | TYMP | |
| SCHEMBL6730011 | 0.81 | POLB (0.30) | POLB | |
| SCHEMBL6835146 | 0.80 | TYMP (0.45) | TYMPHPGDTAAR1HINT1POLB | |
| SCHEMBL8006782 | 0.79 | TAAR1 (0.39) | TYMPHPGDTAAR1HINT1POLB | |
| SCHEMBL4339434 | 0.78 | TYMP (0.37) | TYMPHPGDTAAR1HINT1POLB | |
| SCHEMBL6234136 | 0.78 | TAAR1 (0.39) | TYMPHPGDTAAR1HINT1 | |
| SCHEMBL6831424 | 0.78 | TYMP (0.36) | TYMPHPGDTAAR1HINT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677471-B2 | USED FOR PREPARATION OF OLIGOMERIC COMPOUNDS HAVING PHOSPHITE, PHOSPHODIESTER, PHOSPHOROTHIOATE, PHOSPHORODITHIOATE OR OTHER LINKAGES | ISIS PHARMACEUTICALS, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030149260-A1 | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-6521775-B2 | Genetically engineered oligonucleotides for use as diagnostic and therapeutic tools in gene therapy | ISIS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020055623-A1 | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS. INC. | 2002-05-09 | — | — | US | disclosed |
| US-6326478-B1 | OLIGONUCLEOTIDES AND MEDICAL DIAGNOSIS, METABOLISM | ISIS PHARMACEUTICALS, INC. | 2001-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055623-A1 | Process for the synthesis of oligomeric compounds | PPIP5K2, FDPS, GGPS1 | TYMP 44/4885HPGD 1186/4885TAAR1 4468/4885 |
| US-20030149260-A1 | Process for the synthesis of oligomeric compounds | PPIP5K2, FDPS, GGPS1 | TYMP 44/4885HPGD 1186/4885TAAR1 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.